Literature DB >> 7784286

Antiphospholipid syndrome in a patient with rapidly progressive fibrosing alveolitis.

A D Kelion1, J R Cockcroft, J M Ritter.   

Abstract

The antiphospholipid syndrome is a thrombotic disorder which can occur in a primary form or more classically in systemic lupus erythematosus. An association between cryptogenic fibrosing alveolitis and the antiphospholipid syndrome has not previously been reported. We describe a patient with severe cryptogenic fibrosing alveolitis who developed pulmonary embolism and myocardial infarction in the presence of antiphospholipid antibody. The case also illustrates that worsening respiratory function may represent superimposition of one lung pathology on another, and may not simply be a deterioration of the pre-existing disease.

Entities:  

Mesh:

Year:  1995        PMID: 7784286      PMCID: PMC2398067          DOI: 10.1136/pgmj.71.834.233

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  5 in total

1.  THROMBOSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS DESPITE CIRCULATING ANTICOAGULANTS.

Authors:  E J BOWIE; J H THOMPSON; C A PASCUZZI; C A OWEN
Journal:  J Lab Clin Med       Date:  1963-09

2.  Syndrome of the black swan.

Authors:  E N Harris
Journal:  Br J Rheumatol       Date:  1987-10

Review 3.  The antiphospholipid syndrome: ten years on.

Authors:  G R Hughes
Journal:  Lancet       Date:  1993-08-07       Impact factor: 79.321

4.  Definition and clinical relevance of antibodies to nuclear ribonucleoprotein and other nuclear antigens in patients with cryptogenic fibrosing alveolitis.

Authors:  J R Chapman; P J Charles; P J Venables; P J Thompson; P L Haslam; R N Maini; M E Turner Warwick
Journal:  Am Rev Respir Dis       Date:  1984-09

5.  The significance of antinuclear and DNA antibodies in cryptogenic fibrosing alveolitis.

Authors:  S T Holgate; P Haslam; M Turner-Warwick
Journal:  Thorax       Date:  1983-01       Impact factor: 9.139

  5 in total
  2 in total

Review 1.  The lung in the antiphospholipid syndrome.

Authors:  G Espinosa; R Cervera; J Font; R A Asherson
Journal:  Ann Rheum Dis       Date:  2002-03       Impact factor: 19.103

Review 2.  Unusual manifestations of the antiphospholipid syndrome.

Authors:  Ronald A Asherson; Ricard Cervera
Journal:  Clin Rev Allergy Immunol       Date:  2003-08       Impact factor: 8.667

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.